10X Genomics (DE:1KJ)
NASDAQ:1KJ
1KJ Stock Chart & Stats
€21.28
-€1.48(-9.16%)
At close: 4:00 PM EST
€21.28
-€1.48(-9.16%)
Day’s Range― - ―
52-Week Range€9.16 - €30.19
Previous CloseN/A
Volume0.00
Average Volume (3M)76.00
Market Cap
€3.85B
Enterprise Value€3.67B
Total Cash (Recent Filing)€539.85M
Total Debt (Recent Filing)€81.39M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Aug 06, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding116,877,320
10 Day Avg. Volume23
30 Day Avg. Volume76
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)2.56
Price to Sales (P/S)3.17
P/FCF Ratio15.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€22.67Price Target Upside6.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)-0.67
Revenue Forecast (FY)€539.36M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables GrowthSustained consumables growth reflects the core recurring-revenue engine of 10x's platform. Higher consumables volumes (single-cell and spatial) increase revenue per installed instrument, improve predictability, and create durable pull‑through economics that support margin leverage and long-term revenue visibility.
Balance Sheet ResilienceLow leverage and a substantial equity cushion reduce financial risk and give management flexibility to weather near-term headwinds. Combined with materially improved operating cash flow and positive free cash flow on a TTM basis, the company can fund R&D, Atara scale-up, and go-to-market investments without urgency for dilutive financing.
Product Leadership & TAM Expansion (Atara)Atara represents a structural product step that expands addressable markets for high‑throughput spatial and whole‑transcriptome studies. Its upgradable roadmap and integration with software/GPU processing create a durable platform that can drive future consumables growth, stronger translational adoption, and positioning as a data generator for AI biology.
Bears Say
Sharp TTM Revenue DeclineA steep TTM revenue decline undermines operating leverage and makes profitability improvements fragile. Even with margin gains and cost discipline, a materially lower revenue base limits scale benefits for fixed costs, increases sensitivity to cyclical instrument placements, and raises execution risk over the next several quarters.
Instrument Revenue Headwinds & Customer TimingInstruments seed the installed base that drives recurring consumables. A sustained decline in instrument placements, partly due to customer timing around Atara, reduces future consumables uptake and can depress growth for multiple quarters. Recovery depends on converting preorder demand into placements under constrained capacity.
Limited Atara Capacity & Margin PressureConstrained Atara supply limits near-term revenue conversion from a major product milestone. Additionally, management flags lower instrument margins for Atara and potential migration away from legacy spatial platforms, creating a risk of margin dilution and temporary cannibalization that could temper full-year margin expansion.
10x Genomics News
1KJ FAQ
What was 10X Genomics’s price range in the past 12 months?
10X Genomics lowest stock price was €9.16 and its highest was €30.18 in the past 12 months.
What is 10X Genomics’s market cap?
10X Genomics’s market cap is €3.85B.
When is 10X Genomics’s upcoming earnings report date?
10X Genomics’s upcoming earnings report date is Aug 06, 2026 which is in 41 days.
How were 10X Genomics’s earnings last quarter?
10X Genomics released its earnings results on May 07, 2026. The company reported -€0.087 earnings per share for the quarter, beating the consensus estimate of -€0.239 by €0.152.
Is 10X Genomics overvalued?
According to Wall Street analysts 10X Genomics’s price is currently Undervalued.
Does 10X Genomics pay dividends?
10X Genomics does not currently pay dividends.
What is 10X Genomics’s EPS estimate?
10X Genomics’s EPS estimate is -0.2.
How many shares outstanding does 10X Genomics have?
10X Genomics has 116,877,320 shares outstanding.
What happened to 10X Genomics’s price movement after its last earnings report?
10X Genomics reported an EPS of -€0.087 in its last earnings report, beating expectations of -€0.239. Following the earnings report the stock price went down -5.057%.
Which hedge fund is a major shareholder of 10X Genomics?
Currently, no hedge funds are holding shares in DE:1KJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
10x Genomics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€22.67 (6.52% Upside)
€22.67 (6.52% Upside)
Blogger Sentiment
Bullish
DE:1KJ Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €963.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
206.43%
12-Months-Change
Fundamentals
Return on Equity
-2.86%
Trailing 12-Months
Asset Growth
12.44%
Trailing 12-Months
Company Description
10X Genomics
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
1KJ Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized a major product milestone (Atara) with strong consumables momentum, margin improvement, expense discipline, and a strengthened cash position, balanced against notable near-term headwinds in instrument revenue, limited initial Atara production capacity, and modest full-year growth guidance. Management framed the instrument declines as temporary and incorporated anticipated customer timing shifts into guidance, while positioning Atara and existing platforms to drive longer-term TAM expansion, AI-driven demand, and translational adoption.View all DE:1KJ earnings summaries1KJ Revenue Breakdown
60.32% Americas
22.99% EMEA
8.45% Asia-Pacific excluding China
8.24% China
1KJ Stock 12 Month Forecast
Average Price Target
€22.67
▲(6.52% Upside)
Technical Analysis
Omnicell
―
Schrodinger
―
GeneDx Holdings
―
SOPHiA GENETICS
―
Hinge Health, Inc. Class A
―
Options Prices
Currently, No data available
---